^
Association details:
| Biomarker: | PTEN mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | pifusertib (TAS-117) (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
467P - Dose escalation of TAS-117 in patients with advanced solid tumors
Published date:
09/05/2022
Excerpt:
Pts had advanced/metastatic solid tumors with germline PTEN-inactivating mutations…Unconfirmed partial response was observed in 1 pt with breast cancer; 6 pts had stable disease. A pt with breast cancer had stable disease of >8 months associated with a target lesion tumor shrinkage of ≈15%....TAS-117 showed tolerable toxicity; durable clinical benefit associated with tumor shrinkage was observed in 1 pt.
